Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic β-cells through glycolysis and calcium channels

Understanding the molecular triggers of pancreatic β-cell proliferation may facilitate the development of regenerative therapies for diabetes. Genetic studies have demonstrated an important role for cyclin D2 in β-cell proliferation and mass homeostasis, but its specific function in β-cell division and mechanism of regulation remain unclear. Here, we report that cyclin D2 is present at high levels in the nucleus of quiescent β-cells in vivo. The major regulator of cyclin D2 expression is glucose, acting via glycolysis and calcium channels in the β-cell to control cyclin D2 mRNA levels. Furthermore, cyclin D2 mRNA is down-regulated during S-G(2)-M phases of each β-cell division, via a mechanism that is also affected by glucose metabolism. Thus, glucose metabolism maintains high levels of nuclear cyclin D2 in quiescent β-cells and modulates the down-regulation of cyclin D2 in replicating β-cells. These data challenge the standard model for regulation of cyclin D2 during the cell division cycle and suggest cyclin D2 as a molecular link between glucose levels and β-cell replication.     

Cytoplasmic accumulation of peanut agglutinin-binding glycoconjugates in the cells of primary melanoma correlates with clinical outcome.

In an experimental model, human melanoma cell lines enriched for cells that express the glycoconjugate B-D galactose N-acetyl-D-galactosamine, which reacts with the peanut agglutinin lectin (PNA), are associated with an increase in the frequency of metastases. We previously showed that this glycoconjugate is expressed on the cells of some primary melanomas in humans and that such cells are found selectively in melanomas with a high risk for developing metastases and causing death. Using fixed archival tissues from 99 primary melanomas and lectin histochemistry, we found 65 tumors that contained melanoma cells that were PNA-positive. PNA-reactive cells were not identified in normal melanocytes or in the nevocytes of 24 nevi. PNA-reactive material accumulates adjacent to the nucleus in the area of the Golgi apparatus, initially as a tiny dot, but later in quantities sufficient to displace and indent the nucleus, producing a signet ring cell-like appearance. Tumor cells containing PNA-reactive material were associated with more evolved, deeper, and thicker tumors. Two melanomas up to Clark level II were PNA positive (20%), compared with 60% of level III, 76% of level IV, and 100% of level V. Five of 13 tumors less than 0.76 mm thick (39%) were positive, compared with 50% of tumors 0.76 to 1.49 mm thick, 64% of tumors 1.5 to 2.99 mm thick, and 85% of tumors 3 mm thick or thicker. PNA-reactivity was negatively correlated with disease-free survival (PNA-negative, 49.2+/-23 months; PNA-positive grade 1, 41.6+/-26 months and PNA-positive grade 2, 24.4+/-23 months), survival rate 5 years after initial treatment (PNA-negative, 84.8%; PNA-positive grade 1, 63.8%; and PNA-positive grade 2, 31.3%) and disease-free survival at 5 years after initial treatment (PNA-negative, 69.7%; PNA-positive grade 1, 53.2%; and PNA-positive grade 2, 25%).     

Neurobehavioral changes in mice treated with methylmercury at two different stages of fetal development.

Pregnant C57BL/6 mice were orally given daily doses of 4 or 6 mg/kg of methylmercury chloride (MeHg) or vehicle during either gestational days 7-9 (GD7-9) or days 12-14 (GD12-14). Their female offspring were tested between 6 and 16 weeks of age on a variety of behavioral tasks. Motor coordination on the rotarod and visual discrimination learning in the Y maze were not affected by administration of MeHg either at GD7-9 or at GD12-14. In the open field, the total number of square crossings was lower in mice treated with 4 and 6 mg/kg of MeHg at GD12-14 than in control mice whether the environment was new or familiar, but prenatal administration of MeHg at GD7-9 had no effect on this measure. Administration of MeHg either at GD7-9 or at GD12-14 had no effect on the percentage of central square crossings or on the frequency of rearings in the open field. On spatial alternation training in the T maze, both treated groups in Condition GD7-9 and the group treated with 6 mg/kg at GD12-14 required more sessions to reach the learning criterion than their respective vehicle groups. When spatial alternation was tested with delays, treated groups did not differ from their respective control groups. In the radial arm maze, the performance of mice treated at GD7-9 was normal, but reference memory and working memory were impaired by administration of MeHg at GD12-14. In mice treated with 4 mg/kg of MeHg, reference memory was impaired only on the first block of trials, whereas in mice treated with 6 mg/kg, the deficit persisted on all blocks of trials. Overall, these results indicate that prenatal administration of MeHg at GD12-14 had more detrimental effects on behavioral performance than administration at GD7-9. It reduced locomotor activity and impaired reference memory for egocentric and allocentric spatial information as well as working memory for places.     

Chronic GnRH agonist administration down-regulates platelet serotonin transporter in women undergoing assisted reproductive treatment

The effect of pretreatment with the gonadotropin releasing hormone (GnRH) agonistd-Trp6-LHRH (Decapeptyl) on platelet serotonin transporter in women undergoing assisted reproductive treatment (ART) was investigated and compared with women treated with human menopausal gonadotropin (Pergonal). The study group (n=10) was exposed for 12 days to 3.2 mg Decapeptyl C.R. while a comparison group (n=9) was exposed to 11 days of human meno-pausal gonadotropin (Pergonal). All patients were assessed with the Hamilton depression and anxiety scales before and after treatment, and platelet and plasma samples were collected at the same time points. Plasma levels of estradiol, progesterone, FSH and LH were determined by radioimmunoassay (RIA). Platelet serotonin transporter was labeled using high affinity [³H]imipramine binding. The GnRH analogue induced ovarian suppression as reflected by low plasma estradiol levels, while Pergonal administration induced ovarian stimulation. An elevation in the Hamilton depression and anxiety scale scores was observed in the Decapeptyl treated group; this mood alteration was associated with a significant decrease (19%,P<0.05) in the density (B_max) of platelet [³H]imipramine binding sites. No significant change was observed in the B_max of the Pergonal treated group. These results indicate that ovarian suppression (menopausal-like state) in young women is associated with depressed and anxious mood and decreased serotonin transporter density.